🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GW642444

Found 66 matching trials

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

PHASE1

This study will assess the safety and pharmacokinetics of inhaled GSK573719...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-03-29

Trial ID

NCT01571999

Treatments Being Tested

Inhaled GSK573719 Inhaled GSK573719/vilanterol

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.

PHASE1

GW642444 and GSK233705 are in development for treatment of Chronic Obstruct...

Status

Completed

Location

GSK Investigational Site

Start Date

2008-05-20

Trial ID

NCT00671216

Treatments Being Tested

GSK233705 GW642444 GSK233705 and GW642444 Placebo

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.

PHASE1

The purpose of this study is to characterise the metabolic disposition of r...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-05-18

Trial ID

NCT01286831

Treatments Being Tested

[14C]GW642444

Study to Assess GW642444 in Asthma Patients

PHASE2

This is a study of GW642444M, a long-acting beta 2 specific agonist. This s...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-08

Trial ID

NCT00381667

Treatments Being Tested

GW642444M GW642444H placebo

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma

PHASE3

The primary purpose of the study is to assess the safety and tolerability o...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-07

Trial ID

NCT01244984

Treatments Being Tested

Fluticasone Furoate/GW642444 Inhalation Powder Fluticasone Furoate Inhalation Powder

Asthma Exacerbation Study

PHASE3

This study will establish the safety as well as demonstrate benefit of the ...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-02-22

Trial ID

NCT01086384

Treatments Being Tested

Fluticasone Furoate/GW642444 Fluticasone furoate

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

PHASE3

The primary purpose of the study is to evaluate the safety and tolerability...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-08

Trial ID

NCT01192191

Treatments Being Tested

Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01328444

Treatments Being Tested

GSK 573719 +GW642444 125/25 GSK573719 + GW642444 62.5/25 GSK 573719 125 GSK 573719 62.5 GW642444 25 Plb

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study is designed to compare the effectiveness and safety of Fluticaso...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-03-13

Trial ID

NCT01551758

Treatments Being Tested

FF/VI Existing Maintenance Therapy

Previous Next